1 min read
BIOSpain 2025
Meet Veristat at BIOSpain, October 7 - 9, 2025
Veristat is excited to attend BIOSpain 2025, one of Europe’s largest...
3 min read
With 90 percent of clinical trials failing to reach completion, sponsors need innovative approaches that blend scientific rigor with patient-centered strategies. In this webinar, the expert speakers will explore collaborative pathways that accelerate clinical trial timelines without compromising quality.
They will share proven approaches for navigating the complexities of modern clinical trials. From protocol optimization to patient recruitment strategies and operational excellence, attendees will get to discover how integrating scientific expertise with patient-centric methodologies can transform traditional timelines and drive successful outcomes.
The key topics of discussion will include:
-
Strategic considerations for accelerating all studies, including complex and novel therapy trials.
-
How to effectively integrate the patient voice throughout the clinical trial lifecycle.
-
Practical approaches to compress timelines in monitoring and biometrics.
-
How to design collaborative models that combine patient services, technology and global reach to deliver smarter recruitment, faster timelines and stronger retention without sacrificing scientific integrity.
Watch the Replay
Who Should Attend:
This webinar will appeal to those working in the following areas or having the following job titles:
-
Heads of Clinical Operations/VPs and Directors of Clinical Development
-
Clinical Trial Managers/Patient Recruitment Leads
-
R&D and Scientific Affairs Executives/Biostatisticians and Medical Directors
-
Digital Health and Clinical Innovation Leaders
-
Biotech and pharma/Mid-to-large pharmaceutical companies
-
Emerging and mid-sized biotech firms/Clinical Research Organizations (CROs)
-
Patient recruitment vendors and technology platforms
-
Life science consultancies focused on trial acceleration
What You Will Learn:
-
Strategic considerations for accelerating all studies, including complex and novel therapy trials
-
How to effectively integrate the patient voice throughout the clinical trial lifecycle
-
Practical approaches to compress timelines in monitoring and biometrics
-
How to design collaborative models that combine patient services, technology and global reach to deliver smarter recruitment, faster timelines and stronger retention without sacrificing scientific integrity
Fred Martin
Chief Executive Officer, SubjectWell
Fred Martin brings over 30 years of leadership experience in healthcare, with a passion for building strong cultures, high-performing teams, exceptional customer experiences and technology that meaningfully improves patients’ lives. As CEO of SubjectWell, Fred leads with purpose—driving innovation in clinical trial access and patient recruitment.
Outside of work, Fred is an avid adventurer and lifelong advocate for animal welfare and human rights. Whether skiing, scuba diving, surfing or hiking, he embraces every opportunity to explore the world alongside his husband and their beloved pets.
Outside of work, Fred is an avid adventurer and lifelong advocate for animal welfare and human rights. Whether skiing, scuba diving, surfing or hiking, he embraces every opportunity to explore the world alongside his husband and their beloved pets.
Patrick Flanagan
Chief Executive Officer, Veristat
Patrick Flanagan serves as Chief Executive Officer of Veristat, where he leads the company’s strategy, business operations and financial performance. With a distinguished career spanning consulting, healthcare and software sectors, Patrick has successfully driven commercial growth and international expansion while making significant contributions to global healthcare. Prior to joining Veristat in 2013, he held leadership positions at organizations including A.T. Kearney, Baxter International and Oracle.
Beyond his professional achievements, Patrick is a committed advocate for the rare disease community, having helped raise well over $500K for cancer research through Memorial Sloan Kettering’s Cycle for Survival. He holds a BS from Penn State University and an MBA from Northwestern University’s Kellogg School of Management.
Beyond his professional achievements, Patrick is a committed advocate for the rare disease community, having helped raise well over $500K for cancer research through Memorial Sloan Kettering’s Cycle for Survival. He holds a BS from Penn State University and an MBA from Northwestern University’s Kellogg School of Management.
Dr. Matthias Roos
Director of Scientific Affairs, SubjectWell
With a PhD in Biophysics (summa cum laude) and being a former postdoctoral fellow at MIT focused on virus surface proteins, Dr. Matthias Roos has authored over 15 scientific publications in soft-matter physics and biophysics, earning more than 650 citations and receiving the prestigious Ernst Award from the German Chemical Society. After a fellowship from the German National Academy of Sciences Leopoldina, he transitioned from academia to business with roles at McKinsey & Company and Climedo Health, a clinical trial technology startup, before he joined SubjectWell in 2025. Matthias now combines his scientific and business expertise to achieve lasting impact in the field of clinical trial patient recruitment.
Kim Boericke
Chief Operating Officer, Veristat
Kim Boericke serves as Chief Operating Officer at Veristat and is a member of the Executive Leadership Team, overseeing global operations for clinical trials, projects and programs. With 25 years of clinical research experience, she specializes in clinical trial design and decentralized clinical trial deployment across multiple therapeutic areas and regions. Before joining Veristat in 2024, Kim was COO at Thread and held executive positions at ICON, IQVIA, ClinTrials, INC Research, Duke Clinical Research Institute and i3 Research. A Duke University biology graduate and author of over 15 published articles, Kim actively mentors colleagues, participates in industry forums, advocates for patient centricity and promotes STEM education in her local North Carolina schools.